Мировой рынок лечения уротелиальной карциномы – тенденции отрасли и прогноз до 2030 года

Анализ и размер рынка лечения уротелиальной карциномы

Согласно данным Всемирного фонда исследований рака, рак мочевого пузыря является девятым по распространенности видом рака в мире, и в 2012 году было диагностировано около 430 000 новых случаев. Было засвидетельствовано, что на момент постановки диагноза около 70% случаев являются немышечно-инвазивными, 20% находятся на мышечно-инвазивной стадии и 10% на поздней стадии. Около 59% случаев рака мочевого пузыря происходит в высокоразвитых регионах, таких как Северная Америка и Европа. Экономические и человеческие потери от уротелиального рака означают крайне несоразмерное бремя для здравоохранения.

Data Bridge Market Research анализирует темпы роста мирового рынка лечения уротелиальной карциномы в прогнозируемый период 2023–2030 гг. Ожидаемый среднегодовой темп роста мирового рынка лечения уротелиальной карциномы, как правило, составляет около 20% в указанный прогнозируемый период. Рынок оценивался в 0,81 млрд долларов США в 2022 году и вырастет до 3,48 млрд долларов США к 2030 году. Помимо таких рыночных данных, как рыночная стоимость, темпы роста, сегменты рынка, географический охват, участники рынка и рыночный сценарий, рыночный отчет, подготовленный командой Data Bridge Market Research, также включает в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ конвейера, анализ цен и нормативную базу.

Объем и сегментация рынка лечения уротелиальной карциномы

Market Definition

Urothelial carcinoma is a type of disorder that begins when urothelial cells in the bladder lining changes and grow abnormally leading into the formation of a mass called tumor. It is the most common type of bladder cancer. A person suffering from bladder cancer also have a fair chance of having tumors in ureter, urethra, renal pelvis. The complication occurs when bladder cancers may spread to deeper bladder layers and becomes difficult to control. The typical symptoms of urothelial carcinoma include blood in the urine, pain, irritation in bladder, urination habits changes, edema, night sweats, weight loss and fever.

Global Urothelial Carcinoma Treatment Market Dynamics

Drivers

• Increase in Bladder Cancer

The growing prevalence of bladder cancer across the world supports the market expansion during the forest period. For instance, the Global Cancer Observatory Statistics 2020 reported that bladder cancer and prostate cancer are the leading cancer occurrences around the world. It has also been reported that in 2020, the projected number of new cases of bladder cancer was around 573,278, and that of prostate cancer was 1,414,259 cases among both sexes in the year 2020. Such a high occurrence of cancer globally is boosting the market growth.

• Rising Demand for Chemotherapy

Chemotherapy is considered as the first-line treatment for urothelial cancer. According to the study published in January 2020 titled "Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis", gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) have been considered the first-line treatments for advanced or metastatic urothelial carcinoma (AMUC). Thus, this boosts the market growth.

Opportunities

• Increased Drug Approvals

There are recent approvals from major market players that create much opportunities for the market growth. For instance, the urothelial cancer drugs market is likely to be benefitted from better therapies that are being approved by leading drug regulatory organizations. For instance, in April 2020, China National Medical Products Administration (NMPA) approved tislelizumab developed by BeiGene for the treatment of advanced or metastatic urothelial carcinoma. Numerous novel treatments are predicted to see approvals, further supporting the growth of the market.

• Rising Healthcare Stategies

Numerous strategies has been adopted by the major market players which are boosting the market growth. For instance, in June 2020, Pfizer received the U.S. FDA approval for BAVENCIO. It has been approved as the first-line maintenance treatment among patients who are suffering from advanced or metastatic urothelial carcinoma. Additionally, in April 2020, UroGen Pharma received the U.S. FDA approval for mitomycin gel that has been indicated for the treatment of low-grade upper tract urothelial cancer . This creates more opportunities in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of skilled healthcare professionals who are unaware of the knowledge of the treatment methods for this disease could restrict the growth of the global urothelial carcinoma treatment market during a forecast period.

• High Cost

The huge expenditure of the treatment methods hamper the market growth. The high R&D cost associated with the manufacturing of urothelial cancer drugs, along with increased penetration of generic drugs, is likely to impede the market growth.

This global urothelial carcinoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global urothelial carcinoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

• In April 2022, Pfizer made an equity investment worth USD 25 million in Zentalis Pharmaceuticals, Inc. The aim behind this investment is to help Pfizer to leverage its development capabilities worldwide.
• In June 2022, Roche introduced a human papillomavirus (HPV) self-sampling solution which enables patients to conduct HPV screening in the presence of a healthcare professional. This is anticipated to expand the company’s cancer screening solution line-up.

Global Urothelial Carcinoma Treatment Market Scope

The global urothelial carcinoma treatment market is segmented on the basis of treatment, type, diagnostic test, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Papillary
• Flat Carcinoma

Treatment

• Chemotherapy
• Radiotherapy
• Immunotherapy  

Diagnostic Test

• Urine Cytology
• Biopsy
• Computed tomography scanning
• Ultrasound Imaging
• Cystoscopy
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Urothelial Carcinoma Treatment Market Regional Analysis/Insights

The global urothelial carcinoma treatment market is analyzed and market size insights and trends are provided by treatment, type, diagnostic test, distribution channel and end-user as referenced above.

The major countries covered in the global urothelial carcinoma treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the presence of key manufacturers of the product, increasing research and development activities, healthcare expenditure, and skilled professionals in the region. 

Asia-Pacific dominates the market due to increased new research and developments on urothelial carcinoma treatment market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Urothelial Carcinoma Treatment Market Share Analysis

The global urothelial carcinoma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global urothelial carcinoma treatment market.

Key players operating in the global urothelial carcinoma treatment market include:

• Johnson & Johnson Private Limited (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Bausch Health Companies Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)
• Dendreon Pharmaceuticals LLC (U.S.)
• Eisai Co., Ltd (Japan)
• Genentech, Inc (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• UroGen Pharma, Inc. (U.S.)
• Konninklije Philips N.V. (Netherlands)
• Olympus Corporation (Japan)
• Pacific Edge (New Zealand)
• AroCell AB (Sweden)
• Agilent Technologies Inc. (U.S)

Research Methodology: Global Urothelial Carcinoma Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research — лидер в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их цели. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам требуются данные, в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых необработанных файлах Excel, сводных таблицах (Factbook) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

SKU-55769